Pieter Spee has completed his PhD at the Graduate School of Oncology at the Netherlands Cancer Institute and the University of Leiden in the Netherlands. He has worked 11 years at Novo Nordisk as the Director and Scientific Director of Translational Immunology where he made significant contributions to Lirilumab and Monalizumab, currently in clinical development for various cancers. Presently, he serves as a Chief Technology Officer of FibroTx where he brought the noninvasive biomarker test FibroTx TAP to the market and where he oversees the clinical development of FibroTx SELF, a non-invasive skin diagnostic test intended as point-of-care device for catering personalized skin treatment.   Pieter Spee has completed his PhD at the Graduate School of Oncology at the Netherlands Cancer Institute and the University of Leiden in the Netherlands. He has worked 11 years at Novo Nordisk as the Director and Scientific Director of Translational Immunology where he made significant contributions to Lirilumab and Monalizumab, currently in clinical development for various cancers. Presently, he serves as a Chief Technology Officer of FibroTx where he brought the noninvasive biomarker test FibroTx TAP to the market and where he oversees the clinical development of FibroTx SELF, a non-invasive skin diagnostic test intended as point-of-care device for catering personalized skin treatment.  

Dermatology